Researchers from Koltsovo developed a drug for treatment of depression

| By | Clinical Trials, Drug Development, Preсlinical Studies

According to statistics, more than 4 million people in Russia suffer from mental disorders. This figure includes only those who are registered with the medical institutions. The researchers from Koltsovo have developed a new drug for such patients. It will allow not only to treat depression, but also cope with severe neurological diseases.

The efficacy of new drug was already proven in three animal species, and the next stage will involve clinical tests on humans.

The drug is based on lithium, which has long been known for restoring the mental state in humans. Most often, it is used in the form of lithium carbonate, a special salt.

“There is information that lithium has neuroregenerative and neuroprotective action. If we conduct additional studies and prove that our dosage form also retains these properties of lithium, this will allow in the future to use this drug in case of parkinsonism, Alzheimer’s disease and other neurodegenerative diseases,” said Anastasia Kotlyarova, a junior researcher at the Institute of Clinical and Experimental Lymphology of the Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences.

The drug is being developed under a federal program. Its preclinical tests were successful. Next, the drug will be tested on humans. In the best case scenario, it will take two years before the drug will become available in pharmacies. But even now both scientists and businessmen are convinced that this new product from Siberia will be highly demanded by consumers.